Johnson & Johnson $JNJ Stock Acquired by First Trust Advisors LP

Johnson & Johnson logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • First Trust Advisors increased its Johnson & Johnson stake by 14.8% in the third quarter, adding 190,394 shares to hold about 1.48 million shares worth $390.6 million. Institutional investors collectively own 69.55% of the stock.
  • Johnson & Johnson reported quarterly EPS of $2.59, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.4 billion. The company set 2026 EPS guidance of $11.05–$11.15.
  • The company declared a quarterly dividend of $1.34 per share, equivalent to a 2.0% annualized yield. Analysts’ consensus rating is “Moderate Buy,” with an average price target of $276.54.
  • Five stocks we like better than Johnson & Johnson.

First Trust Advisors LP grew its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,475,271 shares of the company's stock after buying an additional 190,394 shares during the quarter. First Trust Advisors LP owned about 0.06% of Johnson & Johnson worth $390,563,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. National Pension Service lifted its holdings in shares of Johnson & Johnson by 1.3% in the second quarter. National Pension Service now owns 5,226,968 shares of the company's stock valued at $1,327,493,000 after purchasing an additional 67,484 shares in the last quarter. IFP Advisors Inc increased its stake in shares of Johnson & Johnson by 8.8% during the 2nd quarter. IFP Advisors Inc now owns 38,760 shares of the company's stock worth $9,844,000 after purchasing an additional 3,133 shares in the last quarter. Elefante Mark B increased its stake in shares of Johnson & Johnson by 9.8% during the 2nd quarter. Elefante Mark B now owns 28,686 shares of the company's stock worth $7,285,000 after purchasing an additional 2,563 shares in the last quarter. AMG Asset Management Group Inc. raised its position in shares of Johnson & Johnson by 172.0% during the 3rd quarter. AMG Asset Management Group Inc. now owns 3,852 shares of the company's stock worth $1,020,000 after purchasing an additional 2,436 shares during the last quarter. Finally, Gradient Investments LLC raised its position in shares of Johnson & Johnson by 9.9% during the 2nd quarter. Gradient Investments LLC now owns 152,831 shares of the company's stock worth $38,815,000 after purchasing an additional 13,737 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.3%

Shares of JNJ opened at $270.54 on Friday. The stock has a fifty day moving average of $267.53 and a two-hundred day moving average of $250.98. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.74 and a current ratio of 1.02. The company has a market capitalization of $651.27 billion, a PE ratio of 40.99, a price-to-earnings-growth ratio of 2.72 and a beta of 0.22. Johnson & Johnson has a fifty-two week low of $199.90 and a fifty-two week high of $290.25.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. During the same quarter in the prior year, the company posted $2.80 EPS. The business's revenue for the quarter was up 5.9% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, analysts forecast that Johnson & Johnson will post 11.12 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson's dividend payout ratio is 81.21%.

Analysts Set New Price Targets

Several research firms have weighed in on JNJ. UBS Group set a $270.00 price target on Johnson & Johnson in a research report on Wednesday, October 14th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $275.00 to $287.00 and gave the stock an "overweight" rating in a report on Friday, October 16th. Sanford C. Bernstein set a $270.00 price objective on Johnson & Johnson in a research report on Thursday, October 15th. Guggenheim reaffirmed a "buy" rating and set a $287.00 price objective on shares of Johnson & Johnson in a research note on Wednesday, October 7th. Finally, Wall Street Zen cut Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, August 1st. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and a consensus target price of $276.54.

Get Our Latest Stock Report on Johnson & Johnson

Insider Activity

In other Johnson & Johnson news, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total value of $9,230,439.78. Following the completion of the sale, the executive vice president owned 25,447 shares in the company, valued at $6,991,308.78. The trade was a 56.90% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Elizabeth Forminard sold 13,072 shares of the company's stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the transaction, the executive vice president directly owned 16,994 shares of the company's stock, valued at approximately $4,832,923.66. This represents a 43.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 0.16% of the company's stock.

Top Johnson & Johnson Stories

Investors following JNJ have been watching these stories:

  • Positive Sentiment: Phase 4 results for TREMFYA in axial psoriatic arthritis met key endpoints, with significant symptom improvement and more than twice the placebo reduction in MRI-assessed inflammation. The data could strengthen the drug’s commercial prospects. Article
  • Positive Sentiment: The company submitted an FDA application to expand CAPLYTA’s use to bipolar I mania or mixed episodes, supported by two positive Phase 3 studies. Approval is not guaranteed, but another indication could broaden the drug’s growth potential. Article
  • Neutral Sentiment: JPMorgan raised its JNJ price target to $300 from $285 but kept a “neutral” rating, signaling a higher valuation estimate without a change in its overall recommendation. Analyst rating

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

Featured Articles

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ - Free Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Johnson & Johnson Right Now?

Before you consider Johnson & Johnson, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Johnson & Johnson wasn't on the list.

While Johnson & Johnson currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines